Citations

Clear

3485 citation(s) found for "Sy, Sarah".

A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression
Carrasquillo, Minerva M., Allen, Mariet , Burgess, Jeremy D. , Wang, Xue , Strickland, Samantha L. , Aryal, Shivani , Siuda, Joanna , Kachadoorian, Michaela, Medway, Christopher, Younkin, Curtis, Nair, Asha, Chanana, Pritha , Serie, Daniel, Nguyen, Thuy , Lincoln, Sarah, Malphrus, Kimberly G., Morgan, Kevin , Golde, Todd E. , Price, Nathan D. , White, Charles C. , Jager, Philip L. De , Bennett, David A. , Asmann, Yan W. , Petersen, Ronald , Graff‐Radford, Neill R., Younkin, Steven G., Ertekin‐Taner, Nilüfer , Kachadoorian, Michaela L, Younkin, Curtis S, Crook, Julia E. , Bennett, David A. , Carrasquillo, Minerva M. , Siuda, Joanna S. , Wang, Chen , Graff‐Radford, Neill R., Dickson, Dennis W. , Price, Nathan D

Mayo Clinic

Alzheimer's & Dementia | December 8, 2016 | Volume: 13 | Issue: 6 | Pages: 663-673

10.1016/j.jalz.2016.10.005 | PMID 27939925 Get It

AbstractIntroductionWe hypothesized that common Alzheimer's disease (AD)‐associated variants within the triggering receptor expressed on myeloid (TREM) gene cluster influence disease through gene expression.MethodsExpression microarrays on temporal cortex and cerebellum from ∼400 neuropathologically diagnosed subjects and two independent RNAseq replication cohorts were used for expression quantitative trait locus analysis.ResultsA variant within a DNase hypersensitive site 5′ of TREM2, rs9357347‐C, associates with reduced AD risk and increased TREML1 and TREM2 levels (uncorrected P = 6.3 × 10−3 and 4.6 × 10−2, respectively). Meta‐analysis on expression quantitative trait locus results from three independent data sets (n = 1006) confirmed these associations (uncorrected P = 3.4 × 10−2 and 3.5 × 10−3, Bonferroni‐corrected P = 6.7 × 10−2 and 7.1 × 10−3, respectively).DiscussionOur findings point to rs9357347 as a functional regulatory variant that contributes to a protective effect observed at the TREM locus in the International Genomics of Alzheimer's Project genome‐wide association study meta‐analysis and suggest concomitant increase in TREML1 and TREM2 brain levels as a potential mechanism for protection from AD.
Neurovascular control of blood pressure is influenced by aging, sex, and sex hormones
Baker, Sarah E. , Limberg, Jacqueline K. , Ranadive, Sushant M. , Joyner, Michael J. , Ranadive, Sushant M. , Joyner, Michael J , Baker, Sarah E , Ranadive, Sushant

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | November 17, 2016 | Volume: 311 | Issue: 6 | Pages: R1271-R1275

10.1152/ajpregu.00288.2016 | PMID 27856414 Get It

In this review, we highlight that the relationship between muscle sympathetic nerve activity (MSNA) and mean arterial pressure is complex, differs by sex, and changes with age. In young men there is an inverse relationship between MSNA and cardiac output where high MSNA is compensated for by low cardiac output. This inverse relationship is not seen in older men. In young women sympathetic vasoconstriction is offset by β-adrenoreceptor mediated vasodilation, limiting the ability of young women to maintain blood pressure in response to orthostatic stress. However, β-mediated dilation in women is attenuated with age, leading to unopposed α-adrenergic vasoconstriction and a rise in the direct transduction of MSNA into increases in blood pressure. We propose that these changes with age and menopausal status are major contributing factors in the increased prevalence of hypertension in older women. In addition to aging, we highlight that changes in sex hormones in young women (across the menstrual cycle, with oral contraceptive use, or with pregnancy) influence MSNA and the transduction of MSNA into increases in blood pressure. It is likely that the β-adrenergic receptors and/or changes in baroreflex sensitivity play a large role in these sex differences and changes with alterations in sex hormones.
Unusual presentation Of Sjögren‐associated neuropathy with plasma cell‐rich infiltrate
Naddaf, Elie , Berini, Sarah E. , Dyck, P. James B. , Laughlin, Ruple S. , B Dyck, P James, Naddaf, Elie

Mayo Clinic

Muscle & Nerve | November 16, 2016 | Volume: 55 | Issue: 4 | Pages: 605-608

10.1002/mus.25475 | PMID 27862026 Get It

ABSTRACTIntroductionSjögren syndrome is thought to be a lymphocyte‐driven process. Peripheral nervous system involvement occurs in about 20%–25% of patients. A sensory‐predominant, large‐fiber peripheral neuropathy is most common, and it is usually associated with a subacute to chronic presentation.MethodsWe report a rare case of an acute Sjögren‐associated, sensory predominant, length‐dependent peripheral neuropathy mimicking Guillain–Barré syndrome. The patient presented with sensory ataxia preceded by fever and polyarthralgia. She gave a history of years of dry eyes and dry mouth.ResultsShe had a positive Shirmer test, abnormal salivary gland scan, and positive SS‐A and SS‐B antibodies. A sural nerve biopsy showed an unusual, dense, non‐IgG4, polyclonal, plasma‐cell perivascular infiltrate. The patient responded to treatment with weekly pulse intravenous methylprednisolone.ConclusionsSjögren syndrome can present with acute‐onset, sensory predominant peripheral neuropathy. The role of plasma cells in Sjögren syndrome is unexplored and deserves further study. Muscle Nerve 55: 605–608, 2017
A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis
Arceci, R.J., Allen, Carl E. , Jacobsen, Eric D. , Whitlock, James A. , Vassallo, Robert , Morris, Shannon R., Portnoy, Alison, Reedy, Beth Ann, Smith, Deborah A. , Noble, Robert, Murnane, Amy A., Cornfeld, Mark, Heaney, Mark , McClain, Kenneth L. , Vaiselbuh, Sarah R., Dunkel, Ira J. , Rodríguez‐Galindo, Carlos , Vassallo, Robert , McClain, Kenneth L , Allen, Carl E

Mayo Clinic

Pediatric Blood & Cancer | November 2, 2016 | Volume: 64 | Issue: 5 | Pages: No page available

10.1002/pbc.26325 | PMID 27804235 Get It

AbstractBackgroundLangerhans cell histiocytosis (LCH) is a clonal neoplasm characterized by widely varied clinical presentations, including multisystem involvement and systemic inflammatory symptoms. The AKT pathway is relevant to survival and proliferation of dendritic cells, and is also often upregulated in hematopoietic malignancies. A clinical response in an adult patient with LCH participating in the first‐in‐human trial of afuresertib prompted this prospective trial.ProcedureThe population in the current study included treatment‐naïve (n = 7) and recurrent/refractory patients with LCH (n = 10), who received oral afuresertib (125 mg). The majority of patients were treated for > 24 weeks, with four patients receiving treatment for > 48 weeks.ResultsPharmacokinetic analysis showed similar exposures in previously reported patients with other hematologic malignancies. Primary drug‐related toxicities included Grade 1/2 nausea, diarrhea, dyspepsia, and vomiting. Grade 3 toxicities included fatigue, diarrhea, and pain (one of each). Another severe adverse event involved soft tissue necrosis. The overall response rate in evaluable subjects was 33% in treatment‐naïve patients and 28% in patients with recurrent/refractory disease, which did not meet the predefined Bayesian criteria for efficacy.ConclusionAfuresertib has clinical activity in some patients with newly diagnosed and advanced LCH.
A Survey of Perceptions and Acceptance of Wearable Technology for Health Monitoring in a Urological Patient Population
Nehra, Avinash , Gettman, Matthew T., Rivera, Marcelino , Agarwal, Deepak , O’Neil, Daniel A. , Jenkins, Sarah M. , Tollefson, Matthew K. , Viers, Boyd R. , Nehra, Avinash K, Rivera, Marcelino E, Agarwal, Deepak K, Viers, Boyd R

Mayo Clinic

Urology Practice | October 24, 2016 | Volume: 4 | Issue: 6 | Pages: 508-514

10.1016/j.urpr.2016.10.002 | PMID 37300143 Get It

Update on Gender Equity in Immunology, 2001 to 2016
Kovats, Susan , Parent, Michelle A., Gaffen, Sarah L. , Hedrick, Catherine C. , Denzin, Lisa , Raghavan, Malini , Stephens, Robin , Shapiro, Virginia Smith , Kovats, Susan , Raghavan, Malini , Jain, Pooja

Mayo Clinic

The Journal of Immunology | October 18, 2016 | Volume: 197 | Issue: 10 | Pages: 3751-3753

10.4049/jimmunol.1601644 | PMID 27798172 Get It

Abstract In 2001, The American Association of Immunologists Committee on the Status of Women conducted a survey examining the percentage of women faculty members within immunology departments or women in immunology graduate programs across 27 institutions in the United States, comparing it to the percentage of women receiving a Ph.D. Here, we examine the representation of women across these same 27 immunology departments and programs to examine changes in gender equity over the last 15 years.
Awareness and knowledge of Human Papillomavirus (HPV), HPV‐related cancers, and HPV vaccines in an uninsured adult clinic population
Breitkopf, Carmen Radecki , Findley, Victoria, Jacobson, Debra J., Wilson, Patrick M. , Albertie, Monica, Colón‐Otero, Gerardo , Radecki Breitkopf, Carmen, Finney Rutten, Lila J, Jacobson, Robert M. , Rutten, Lila J. Finney

Mayo Clinic

Cancer Medicine | October 17, 2016 | Volume: 5 | Issue: 11 | Pages: 3346-3352

10.1002/cam4.933 | PMID 27748078 Get It

AbstractHuman papillomavirus (HPV) vaccines offer primary prevention of cervical cancer and protection against other HPV‐associated cancers. HPV vaccine coverage in the United States (U.S.) remains low, particularly among older adolescents/young adults, and the uninsured. We assessed awareness and knowledge of HPV disease, HPV‐related cancers, and HPV vaccines among working, uninsured adults. Data from the 2014 Health Information National Trends Survey (HINTS 4, Cycle 4) were used as a benchmark. Patients were surveyed in late 2014 at the Volunteers in Medicine free clinic in Duval County, Florida. Surveys contained validated measures of HPV disease and vaccine knowledge; HPV‐related cancer knowledge was also assessed. Two‐hundred and ninety‐six surveys were analyzable with an 84% participation rate. Half (50.3%) of participants had heard of HPV, and 32.1% had heard of the HPV vaccine; in HINTS, these estimates were 63.6% and 62.7%, respectively (both P < 0.0001). In adjusted models, high HPV disease knowledge was associated with white race and increased education; high vaccine knowledge was associated with white race, increased education, and female sex. Recognition of HPV as a causative agent was 43.9% for cervical, 9.1% for anal, and 11.1% for throat cancers. For all HPV‐associated cancers, participants had lower knowledge/recognition relative to HINTS. The uninsured, socioeconomically disadvantaged adults we surveyed were unaware of a ubiquitous virus that can cause cancer and the existence of a vaccine to protect against it. These findings point to settings and populations in which initiatives to promote HPV vaccination as a cancer prevention tool remain critical.